Shanghai MicuRx Pharmaceutical Company Description

Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs.

It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour.

Shanghai MicuRx Pharmaceutical Co., Ltd. was founded in 2007 and is based in Shanghai, China.

Shanghai MicuRx Pharmaceutical Co., Ltd.

Country	China
Founded	2007
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	177
CEO	Yuan Zhengyu

Contact Details

Address: 53, Edison Road Shanghai China
Phone	86 21 5090 0550
Website	micurxchina.com

Stock Details

Ticker Symbol	688373
Exchange	Shanghai Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
SIC Code	2836

Key Executives

Name	Position
Dr. Yuan Zhengyu Ph.D.	Chief Executive Officer and Chairman
Zhiyue Li	Director, Deputy GM and Chief Financial Officer
Xinghai Wang	Deputy GM and Chief Technology Officer
Hong Yuan	Deputy GM and Chief Clinical Officer
Dongming Zhao	General Manager of Kerui Kaisi
Liang Lu	Chairman of the Supervisory Board, Director of the Quality and Compliance Department
Liu Jingian	Head of Corporate Chemistry
Wang Wen	Head of Biological Department
Youyin Xu	Deputy GM and Head of Commercial Operations